BeiGene
BGNE
#919
Rank
HK$156.68 B
Marketcap
HK$1,432
Share price
0.49%
Change (1 day)
29.31%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

ESG Reports

Thumbnail BeiGene
 ESG Report 2022

ESG Report 2022

Language: English

View ESG Report
Thumbnail BeiGene
 ESG Report 2021

ESG Report 2021

Language: English

View ESG Report
Thumbnail BeiGene
 ESG Report 2020

ESG Report 2020

Language: English

View ESG Report
Thumbnail BeiGene
 ESG Report 2019

ESG Report 2019

Language: English

View ESG Report